ChemoCentryx, Inc. (CCXI): Price and Financial Metrics
GET POWR RATINGS... FREE!
CCXI POWR Grades
- CCXI scores best on the Growth dimension, with a Growth rank ahead of 75.75% of US stocks.
- The strongest trend for CCXI is in Growth, which has been heading up over the past 179 days.
- CCXI's current lowest rank is in the Stability metric (where it is better than 9.26% of US stocks).
CCXI Stock Summary
- With a price/sales ratio of 56.52, ChemoCentryx Inc has a higher such ratio than 96.45% of stocks in our set.
- Revenue growth over the past 12 months for ChemoCentryx Inc comes in at -50.34%, a number that bests only 3.17% of the US stocks we're tracking.
- The volatility of ChemoCentryx Inc's share price is greater than that of 90.76% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to ChemoCentryx Inc are HRTX, DBX, ADCT, QLGN, and CLSN.
- CCXI's SEC filings can be seen here. And to visit ChemoCentryx Inc's official web site, go to www.chemocentryx.com.
CCXI Valuation Summary
- CCXI's EV/EBIT ratio is -9.1; this is 131.06% lower than that of the median Healthcare stock.
- CCXI's price/sales ratio has moved up 40 over the prior 116 months.
- CCXI's price/earnings ratio has moved up 116.3 over the prior 116 months.
Below are key valuation metrics over time for CCXI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CCXI | 2021-08-31 | 51.1 | 3.3 | -9.0 | -9.1 |
| CCXI | 2021-08-30 | 49.9 | 3.3 | -8.8 | -8.9 |
| CCXI | 2021-08-27 | 50.9 | 3.3 | -9.0 | -9.1 |
| CCXI | 2021-08-26 | 50.0 | 3.3 | -8.8 | -8.9 |
| CCXI | 2021-08-25 | 49.0 | 3.2 | -8.6 | -8.8 |
| CCXI | 2021-08-24 | 48.1 | 3.1 | -8.5 | -8.6 |
CCXI Growth Metrics
- The year over year revenue growth rate now stands at 104.79%.
- Its year over year net cashflow from operations growth rate is now at 5.07%.
- Its 2 year net cashflow from operations growth rate is now at -501.51%.
The table below shows CCXI's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 34.267 | -83.958 | -121.103 |
| 2021-06-30 | 21.609 | -74.797 | -122.856 |
| 2021-03-31 | 69.236 | -75.264 | -63.38 |
| 2020-12-31 | 64.891 | -81.143 | -55.356 |
| 2020-09-30 | 70.58 | -82.149 | -41.008 |
| 2020-06-30 | 76.076 | -82.726 | -29.81 |
CCXI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CCXI has a Quality Grade of D, ranking ahead of 9.23% of graded US stocks.
- CCXI's asset turnover comes in at 0.043 -- ranking 329th of 682 Pharmaceutical Products stocks.
- LUMO, CBAY, and BPTH are the stocks whose asset turnover ratios are most correlated with CCXI.
The table below shows CCXI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.043 | 1 | -0.262 |
| 2021-03-31 | 0.132 | 1 | -0.148 |
| 2020-12-31 | 0.145 | 1 | -0.163 |
| 2020-09-30 | 0.191 | 1 | -0.166 |
| 2020-06-30 | 0.262 | 1 | -0.190 |
| 2020-03-31 | 0.159 | 1 | -0.476 |
CCXI Price Target
For more insight on analysts targets of CCXI, see our CCXI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.50 | Average Broker Recommendation | 1.31 (Strong Buy) |
CCXI Stock Price Chart Interactive Chart >
CCXI Price/Volume Stats
| Current price | $26.15 | 52-week high | $42.16 |
| Prev. close | $27.51 | 52-week low | $12.71 |
| Day low | $25.13 | Volume | 2,344,600 |
| Day high | $27.79 | Avg. volume | 1,403,930 |
| 50-day MA | $21.47 | Dividend yield | N/A |
| 200-day MA | $27.64 | Market Cap | 1.86B |
ChemoCentryx, Inc. (CCXI) Company Bio
ChemoCentryx, Inc. focuses on the discovery, development, and commercialization of orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. The company was founded in 1997 and is based in Mountain View, California.
Latest CCXI News From Around the Web
Below are the latest news stories about ChemoCentryx Inc that investors may wish to consider to help them evaluate CCXI as an investment opportunity.
ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536- |
ChemoCentryx (CCXI) Receives a Buy from H.C. WainwrightIn a report released today, Edward White from H.C. Wainwright maintained a Buy rating on ChemoCentryx (CCXI – Research Report), with a price target of $101.00. The company's shares closed last Tuesday at $31.51. According to TipRanks.com, White 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.4% and a 32.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Aeglea Biotherapeutics. ChemoCentryx has an analyst consensus of Strong Buy, with a price target consensus of $62.75, implying a 101.9% upside from current levels. |
ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceSAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 th at 5:00 p.m. Eastern Time. |
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue EstimatesEnanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -30.97% and 3.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Lisanti Capital Growth, LLC Buys Saia Inc, Knight-Swift Transportation Holdings Inc, ...Investment company Lisanti Capital Growth, LLC (Current Portfolio) buys Saia Inc, Knight-Swift Transportation Holdings Inc, Cytokinetics Inc, ArcBest Corp, Inspire Medical Systems Inc, sells CommVault Systems Inc, Varonis Systems Inc, Sprout Social Inc, Acadia Healthcare Co Inc, Crocs Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Lisanti Capital Growth, LLC. |
CCXI Price Returns
| 1-mo | 16.79% |
| 3-mo | 9.14% |
| 6-mo | -29.17% |
| 1-year | 89.91% |
| 3-year | 200.92% |
| 5-year | 197.84% |
| YTD | -28.18% |
| 2021 | -41.20% |
| 2020 | 56.56% |
| 2019 | 262.51% |
| 2018 | 83.36% |
| 2017 | -19.59% |
Continue Researching CCXI
Want to do more research on ChemoCentryx Inc's stock and its price? Try the links below:ChemoCentryx Inc (CCXI) Stock Price | Nasdaq
ChemoCentryx Inc (CCXI) Stock Quote, History and News - Yahoo Finance
ChemoCentryx Inc (CCXI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...